BACKGROUND/AIMS: Response adaptive randomization has many polarizing properties in two-arm settings comparing control to a single treatment. The generalization of these features to the multiple arm setting has been less explored, and existing comparisons in the literature reach disparate conclusions. We investigate several generalizations of two-arm response adaptive randomization methods relating to control allocation in multiple arm trials, exploring how critiques of response adaptive randomization generalize to the multiple arm setting. METHODS: We perform a simulation study to investigate multiple control allocation schemes within response adaptive randomization, comparing the designs on metrics such as power, arm selection, mean square error, and the treatment of patients within the trial. RESULTS: The results indicate that the generalization of two-arm response adaptive randomization concerns is variable and depends on the form of control allocation employed. The concerns are amplified when control allocation may be reduced over the course of the trial but are mitigated in the methods considered when control allocation is maintained or increased during the trial. In our chosen example, we find minimal advantage to increasing, as opposed to maintaining, control allocation; however, this result reflects an extremely limited exploration of methods for increasing control allocation. CONCLUSION: Selection of control allocation in multiple arm response adaptive randomization has a large effect on the performance of the design. Some disparate comparisons of response adaptive randomization to alternative paradigms may be partially explained by these results. In future comparisons, control allocation for multiple arm response adaptive randomization should be chosen to keep in mind the appropriate match between control allocation in response adaptive randomization and the metric or metrics of interest.
BACKGROUND/AIMS: Response adaptive randomization has many polarizing properties in two-arm settings comparing control to a single treatment. The generalization of these features to the multiple arm setting has been less explored, and existing comparisons in the literature reach disparate conclusions. We investigate several generalizations of two-arm response adaptive randomization methods relating to control allocation in multiple arm trials, exploring how critiques of response adaptive randomization generalize to the multiple arm setting. METHODS: We perform a simulation study to investigate multiple control allocation schemes within response adaptive randomization, comparing the designs on metrics such as power, arm selection, mean square error, and the treatment of patients within the trial. RESULTS: The results indicate that the generalization of two-arm response adaptive randomization concerns is variable and depends on the form of control allocation employed. The concerns are amplified when control allocation may be reduced over the course of the trial but are mitigated in the methods considered when control allocation is maintained or increased during the trial. In our chosen example, we find minimal advantage to increasing, as opposed to maintaining, control allocation; however, this result reflects an extremely limited exploration of methods for increasing control allocation. CONCLUSION: Selection of control allocation in multiple arm response adaptive randomization has a large effect on the performance of the design. Some disparate comparisons of response adaptive randomization to alternative paradigms may be partially explained by these results. In future comparisons, control allocation for multiple arm response adaptive randomization should be chosen to keep in mind the appropriate match between control allocation in response adaptive randomization and the metric or metrics of interest.
Entities:
Keywords:
Multiple arm clinical trial; control allocation; response adaptive randomization
Authors: Alessio Crippa; Bram De Laere; Andrea Discacciati; Berit Larsson; Jason T Connor; Erin E Gabriel; Camilla Thellenberg; Elin Jänes; Gunilla Enblad; Anders Ullen; Marie Hjälm-Eriksson; Jan Oldenburg; Piet Ost; Johan Lindberg; Martin Eklund; Henrik Grönberg Journal: Trials Date: 2020-06-26 Impact factor: 2.279
Authors: John M VanBuren; T Charles Casper; Daniel K Nishijima; Nathan Kuppermann; Roger J Lewis; J Michael Dean; Anna McGlothlin Journal: Trials Date: 2021-11-04 Impact factor: 2.279
Authors: Anders Granholm; Waleed Alhazzani; Lennie P G Derde; Derek C Angus; Fernando G Zampieri; Naomi E Hammond; Rob Mac Sweeney; Sheila N Myatra; Elie Azoulay; Kathryn Rowan; Paul J Young; Anders Perner; Morten Hylander Møller Journal: Intensive Care Med Date: 2021-12-02 Impact factor: 41.787
Authors: Derek C Angus; Scott Berry; Roger J Lewis; Farah Al-Beidh; Yaseen Arabi; Wilma van Bentum-Puijk; Zahra Bhimani; Marc Bonten; Kristine Broglio; Frank Brunkhorst; Allen C Cheng; Jean-Daniel Chiche; Menno De Jong; Michelle Detry; Herman Goossens; Anthony Gordon; Cameron Green; Alisa M Higgins; Sebastiaan J Hullegie; Peter Kruger; Francois Lamontagne; Edward Litton; John Marshall; Anna McGlothlin; Shay McGuinness; Paul Mouncey; Srinivas Murthy; Alistair Nichol; Genevieve K O'Neill; Rachael Parke; Jane Parker; Gernot Rohde; Kathryn Rowan; Anne Turner; Paul Young; Lennie Derde; Colin McArthur; Steven A Webb Journal: Ann Am Thorac Soc Date: 2020-07
Authors: Thomas Burnett; Pavel Mozgunov; Philip Pallmann; Sofia S Villar; Graham M Wheeler; Thomas Jaki Journal: BMC Med Date: 2020-11-19 Impact factor: 8.775